Allergan takes Linzess on a run with differentiation push

Carly Helfand Every drugmaker wants to find differentiators for their products. And for Ironwood, it was obvious. "Is this a constipation drug that improves abdominal symptoms, ...

Galapagos moves AbbVie-partnered drug into PhI as multipronged attack on CF takes shape

Nick Paul Taylor Galapagos has kicked off a Phase I trial of its AbbVie-partnered cystic fibrosis (CF) drug, GLPG2222. The start of the trial marks another milestone in the rolling ...

NHS watchdog takes issue with Pfizer exec’s new role on foundation trust’s board

Tracy Staton A top Pfizer executive joined the board of a National Health Service Trust in England, triggering questions about potential conflicts of interest, an NHS-focused news service ...

NeuroVive takes a 10% stake in partner Isomerase

Damian Garde Swedish drug developer NeuroVive Pharmaceutical is cozying up to R&D partner Isomerase Therapeutics, buying a stake in the company as the two move together ...

Pneumonia-stricken Valeant chief takes medical leave of absence

Carly Helfand Last week, Valeant confirmed that CEO J. Michael Pearson had been hospitalized with a severe case of pneumonia–and now, he's taking a medical leave of absence. FiercePharma ...

Amgen takes to Europe with its Humira biosimilar

Damian Garde Amgen submitted its copy of AbbVie's blockbuster Humira to European regulators, angling to siphon revenues from the world's top-selling drug as rivals develop biosimilars ...

Boehringer takes a neuroscience approach to obesity with latest deal

Damian Garde Boehringer Ingelheim is pairing up with a small California biotech to explore the role circuits in the nervous system play in obesity, scouting for drug targets that could ...

DOJ criminal probe takes a look at trade associations

Eric Palmer For more than a year, the Justice Department (DOJ) has been pursuing a criminal investigation into the possibility of pricing collusion among makers of generics. Three companies ...

Gilead takes a $125M FDA shortcut with its latest HIV combo

Damian Garde Last year, Gilead Sciences paid $ 125 million for a ticket promising a speedy FDA review. Now the Big Biotech is cashing it in, submitting a combination HIV treatment ...

Oxford BioMedica takes out $50M loan to service Novartis CAR-T alliance

Nick Paul Taylor Oxford BioMedica has secured a $ 50 million (€45 million) loan, half of which it will take out immediately to expand its laboratory and manufacturing facilities. ...

Caforio takes CEO role as BMS faces tough year with promising new drugs

Eric Palmer Trained in his native Italy as a doctor, Giovanni Caforio speaks not only English and Italian, but also Spanish, French and Portuguese. As he steps into the CEO role today ...

Intrexon takes a $60M flyer on a synthetic biology startup

Damian Garde Billionaire R.J. Kirk's Intrexon has signed a $ 60 million deal to acquire ActoGeniX, a Belgian biotech at work on oral drugs designed to generate therapeutic proteins ...
Page 1 of 41234
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS